TEDCO was created by the Maryland State Legislature in 1998 to facilitate the transfer and commercialization of technology from Maryland’s research universities and federal labs into the marketplace and to assist in the creation and growth of technology-based businesses in all regions of the State.   TEDCO is an independent organization that strives to be Maryland’s lead source for entrepreneurial business assistance and seed funding for the development of startup companies in Maryland’s innovation economy.   In Maryland and beyond, TEDCO is a resource of mentoring, funding and networking for entrepreneurs and start-ups that need guidance as they bring innovative concepts to market.   TEDCO is more than an early stage funding resource. It is the hub of Maryland’s entrepreneurial network where startups find mentors, organizational assistance, facilities for daily operations, and a roadmap for success.

TEDCO

National Institutes of Health is a biomedical research facility in the United States. It is affiliated with the United States Department of Health and Human Services. It is the primary agency of the United States government responsible for biomedical and health-related research. It conducts its own scientific research through its Intramural Research Program (IRP) and provides major biomedical research funding to non-NIH research facilities through its Extramural Research Program. National Institutes of Health has 1,200 principal investigators and more than 4,000 postdoctoral fellows in basic, translational, and clinical research. It comprises 27 separate institutes and centers that conduct research in different disciplines of biomedical science. With scientific accomplishments such as the discovery of fluoride to prevent tooth decay, the use of lithium to manage bipolar disorder, the creation of vaccines against hepatitis, Haemophilus influenzae (HIB), and human papillomavirus, National Institutes of Health has many agencies under its control. National Institutes of Health was established in 1887. It is based in Bethesda, Maryland.

National Institutes of Health

Maryland Industrial Partnerships promotes the development of products and processes through industry and university research partnerships. MIPS provides matching funding to help Maryland businesses pay for university research. Companies initiate projects to satisfy their own R&D objectives.

Maryland Industrial Partnerships (MIPs)

UM Ventures is a joint initiative of the University of Maryland, Baltimore and the University of Maryland, College Park to commercialize technologies and expand industry collaboration by engaging partners in industry and social ventures. By engaging directly with external partners, it will bring new investment, expanded markets, and more startup ventures.

UM Ventures

MedTech Innovator is the industry’s nonprofit global competition and accelerator for medical device, digital health and diagnostic companies. Our mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system. MedTech Innovator annually features 100 companies that address one or more of the transformative themes identified in an annual survey of leading manufacturers and providers.

MedTech Innovator

Hunniwell Healthcare Fund I invests in extensions of proven technologies within overlooked segments of the medical device space from the heart of Silicon Valley. It provides entrepreneurs with a longer runway to develop a more complete portfolio of products before monetizing their innovations. They leverage their entrepreneurial spirit, operational experience, and global networks to help companies achieve higher profitability earlier, through improved market access, greater capital efficiency in R&D, and lower manufacturing costs.

Hunniwell Lake Ventures

CoapTech

CoapTech is an early-stage medical device company aiming to improve medical care delivery for patients young and old around the world. The company seeks to bring a series of breakthrough medical devices to worldwide markets, leveraging a patent-pending, disruptive technology called Coaptive Ultrasound which is owned by the company. Its devices reduce healthcare costs and improve safety, quality, patient experience, and access to services around the globe. Invented by Dr. Tropello, CoapTech delivers a novel platform technology combining magnetic attraction for device placement guidance, and low-cost, point-of-care ultrasound for visual feedback in diagnostic, interventional, and therapeutic procedures. Strong rare-earth magnets are used to manually guide devices placed inside the human body, while real-time, low-cost ultrasound provides visual feedback to the clinician to ensure safety. This platform technology, invented by the company founder, has the potential to disrupt multiple medical procedures, substantially reducing costs while improving safety and patient experience. Their lead use case, selected because of its low risk, clear FDA pathway, and strong commercial viability, is for the insertion of gastrostomy tubes. They have defined the use of Coaptive Ultrasound to perform this novel gastrostomy procedure, as Percutaneous Ultrasound Gastrostomy (PUG). Briefly, PUG is a point-of-care (as opposed to the operating room) procedure for inserting gastrostomy tubes which can be quickly and easily performed by non-surgical providers. It employs readily available medical devices such as ultrasound, feeding tubes, guide wires, and dilators.

CoapTech is a Baltimore-based medical device company that has developed the PUMA System, a new platform that enables ultrasound procedures within the hollow organs of the body. The company's flagship product, the PUMA-G System, is an FDA-cleared and CE-marked device for ultrasound gastrostomy tube placement in adults. It utilizes magnetically aligned catheters and external magnets to visualize tissue and organs in real-time during the procedure, eliminating the need for radiation exposure.

CoapTech Announces IDE Approval from FDA to Initiate Clinical Trial for its PUMA-G Peds System for Pediatric Gastrostomy

Published Study Results Demonstrate Substantial Length of Stay and Hospital Cost Reductions with Use of CoapTech's PUMA-G System™ for Gastrostomy When Compared to Usual Care Methods

CoapTech prepares clinical trials for its ultrasound

Instead of outsourcing to California, this Baltimore medtech company is now making its devices at home

UMB's CoapTech awarded $50K seed fund grant

CoapTech Awarded Seed Fund Grant from Pennsylvania Pediatric Device Consortium

Private company analysis for CoapTech

CoapTech gets FDA approval for clinical trial of pediatric feeding tube system

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

CoapTech prepares clinical trials for its ultrasound-based device

CoapTech is a Baltimore-based medical device company that has developed the PUMA System, a new platform that enables ultrasound procedures within the hollow organs of the body. The company's flagship product, the PUMA-G System, is an FDA-cleared and CE-marked device for ultrasound gastrostomy tube placement in adults. It utilizes magnetically aligned catheters and external magnets to visualize tissue and organs in real-time during the procedure, eliminating the need for radiation exposure.
CoapTech's PUMA technology has expanded to include the PUMA-G Peds System for pediatric gastrostomy, the PUMA-G XL for patients with higher BMIs, and the PUMA-J for jejunum tube placement. The PUMA-J has received FDA approval for human studies at the University of Maryland Medical System.
A study conducted at the University of Maryland Baltimore Washington Medical Center in 2022 demonstrated that using the PUMA-G System reduced intensive care unit and hospital lengths of stay by five and 8.7 days, respectively, compared to traditional methods. Additionally, total hospital costs were reduced by over USD 26,000 per patient when utilizing the PUMA-G System.
In April 2024, CoapTech announced that it had brought the manufacturing of the PUMA-G System entirely to Baltimore after previously outsourcing production to California. This move aligns with the company's goal of building its products locally.

Convergent Dental, Inc. is a privately owned dental equipment and technology company. Its flagship product, Solea, is the only CO2 laser cleared by the FDA for all-tissue indications, delivering an anesthesia-free, blood-free, and suture-free experience for dentists and patients. Solea represents a breakthrough in dental laser technology, offering a distinct experience compared to traditional instruments or earlier laser treatments.
Solea is a novel 9.3-micron CO2 laser that nears the peak absorption of hydroxyapatite (enamel), enabling it to vaporize enamel with speed and precision. This unique wavelength, coupled with computer-controlled motors (galvos) that manipulate the beam thousands of times per second, allows dentists to perform procedures ranging from hard tissue to soft tissue with total control and efficiency.
A key feature of Solea is its variable-speed foot pedal, which lets dentists seamlessly transition from hard to soft tissue by adjusting the pressure applied. This intuitive design streamlines the learning curve for dentists accustomed to using a drill. Solea's three ergonomic handpieces – Contra-Angle, Straight, and Ultraguide – further enhance its versatility across various procedures.
Solea not only improves patient experiences but also offers practice benefits such as increased productivity, new patient flow, and efficiency gains. In October 2022, Convergent Dental received FDA clearance for Solea to aid in reducing mineral loss in dental enamel, protecting teeth against acid attack and caries development. This breakthrough application was commercially launched in November 2023 under the name Solea Protect.

Convergent Dental

Ossio is an orthopedic fixation technology company that has developed OSSIOfiber Intelligent Bone Regeneration Technology, a breakthrough implant material designed to securely fixate and fully integrate into the body's native anatomy without leaving any permanent hardware behind. This technology addresses the limitations of conventional metal and resorbable implants, combining unparalleled mechanical strength with natural bone healing.
Made from a proprietary mineral fiber matrix held together by a naturally degradable polymer, OSSIOfiber implants provide surgeons with a more biologically friendly way to restore patient stability and mobility. These implants are engineered to provide the strength required for functional fixation while allowing full integration into the native bone without adverse biological response.
Ossio's product portfolio includes compression screws, trimmable fixation nails, hammertoe fixation systems, suture anchors, and compression staples, all made with OSSIOfiber technology. These implants have received multiple FDA clearances since 2019, and the company has initiated commercialization of its products in the US. As of March 2022, over 6,000 implantations of OSSIOfiber products had been performed, demonstrating adoption of this innovative technology.
OSSIOfiber Intelligent Bone Regeneration Technology can address various surgical applications through the manufacturing of implant designs like nails, screws, staples, anchors, and plates. Ossio plans to pursue multiple applications in distal extremities, trauma, sports, reconstruction, pediatrics, and spine segments.
In February 2023, Ossio launched the world's first and only non-permanent compression staple made with OSSIOfiber technology, designed for predictable bone in-growth, regeneration, and replacement.

Ossio

Casana is a healthcare technology company that has developed the Heart Seat, an innovative toilet seat that enables effortless, integrated, and consistent in-home health monitoring. The Heart Seat is a replacement for a standard toilet seat and is designed to measure key clinical parameters such as heart rate, blood oxygen saturation (SpO2), and blood pressure.
In May 2023, Casana received FDA clearance for the Heart Seat to measure heart rate and SpO2 in adults aged 22 years and older, weighing between 90 to 350 pounds. The company plans to file for additional indications, including systolic and diastolic blood pressure, with the goal of launching the product in the market by the end of 2023.
The Heart Seat is equipped with sensors that passively capture health data whenever the seat is used, eliminating the need for user compliance or behavior changes. The data is automatically uploaded to the Casana Cloud, where it can be viewed by healthcare providers, enabling them to monitor patients' health trends and respond to changes in near real-time.
Casana's technology allows for the effortless collection of consistent and reliable data, assisting medical teams in monitoring chronic conditions beyond the hospital or physician's office. The company aims to unlock a new category in healthcare technologies that enables seamless, integrated, and continuous in-home health monitoring.
In January 2022, Casana was acquired by an undisclosed entity, further accelerating the commercialization of the Heart Seat.

Casana

Neurent Medical is a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, particularly chronic rhinitis. The company's flagship product is the NEUROMARK System, a device that received US Food and Drug Administration (FDA) 510(k) clearance in October 2021.
The NEUROMARK System is designed to gently apply controlled low-power radio frequency (RF) energy to target regions of the nasal cavity, disrupting the parasympathetic nerve signals that can trigger an inflammatory response. This alleviates chronic rhinitis symptoms such as persistent congestion, rhinorrhea (runny nose), swelling of the mucosal membrane, sneezing, and nasal itching. The system's unique flexible leaflet design and proprietary smart algorithms enable precise neurolysis (disruption) of the posterior nasal nerves (PNN) and accessory pathways, accommodating a range of patient anatomies while maintaining mucosal and vascular integrity.
Neurent Medical announced the limited market release of the NEUROMARK System in the US in February 2023, following the establishment of a new Category I Current Procedural Terminology (CPT) code by the American Medical Association (AMA) for PNN procedures, effective January 2024. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) also endorsed the PNN procedure in 2023.

Neurent Medical

Genetesis is a medical imaging company specializing in biomagnetic cardiac imaging solutions. It has developed CardioFlux, a flagship magnetocardiography (MCG) system that non-invasively identifies myocardial ischemia, a condition where blood flow to the heart muscle is reduced. The technology measures the magnetic fields generated by the heart's electrical activity to detect ischemia within minutes, without using pharmaceuticals or radiation. CardioFlux MCG is designed to provide advanced imaging while prioritizing patient comfort.
The company's solutions target the diagnosis of coronary microvascular disease (CMD), a condition that has been challenging to identify due to a lack of effective functional diagnostics. By offering an accurate and rapid test for CMD, Genetesis aims to address an unmet clinical need and enable timely management of the condition.
In April 2023, the US Food and Drug Administration (FDA) granted CardioFlux MCG Breakthrough Device designation for the non-invasive diagnosis of myocardial ischemia in patients suspected of having CMD.
Genetesis was founded in 2013 and is headquartered in Mason, Ohio. The company has received over USD 40 million in funding to date, including a USD 17.5 million Series C round in October 2022. In April 2020, TDK Ventures, the corporate venture capital arm of TDK Corporation, invested in Genetesis, providing access to TDK's expertise in areas like biomagnetic sensors and magnetic noise suppression.

Genetesis

Companies that develop diagnostic devices used in a hospital setting to identify a disease, condition, or injury, such as imaging systems and endoscopes

Companies that develop implantable medical devices designed to be surgically placed inside the human body, either temporarily or permanently, including devices such as pacemakers, artificial joints, stents, and cochlear implants

Companies that develop non-surgical devices that are used in a procedure or intervention to cure or relieve a patient from an illness or disease such as laser treatments, dental equipment, and wound care management

Companies that develop monitoring devices that are used in a hospital setting to measure patient vital signs and ensure patient well-being post-treatment, such as cardiac and respiratory monitoring systems

Providers of software that enhances the functionality of medical device hardware (diagnosis, treatment, and monitoring)

Companies that develop surgical devices involving invasive interventions (cutting into a patient's body tissues) to treat, cure, or relieve a patient of an illness or disease

Companies that develop devices to administer pharmaceutical substances into a patient's body, ensuring controlled release or targeted delivery, specifically for use in clinical settings to treat or manage medical conditions effectively

Providers of software that helps manage risks, ensure quality, and streamline audit processes during medical device development

IoT connects devices to EHR systems for precise patient diagnosis and treatment support

Devices are linked to software platforms that use digital technologies such as AI/ML and VR

Startups leverage AI/ML and deep learning to support patient diagnosis and early detection

CoapTech

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless